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Abstract 
Three priority areas in the prevention, diagnosis and management of acute rheumatic fever 
(ARF) and rheumatic heart disease (RHD) were identified and discussed in detail: 
1. Echocardiography and screening/diagnosis of RHD - Given the existing uncertainty it 
remains premature to advocate for or to incorporate echocardiographic screening for 
RHD into Australian clinical practice. Further research is currently being undertaken to 
evaluate the potential for echocardiography screening. 
2. Secondary prophylaxis – Secondary prophylaxis (long acting benzathine penicillin 
injections) must be seen as a priority. Systems-based approaches are necessary with a 
focus on the development and evaluation of primary health care-based or led strategies 
incorporating effective health information management systems. Better/novel systems 
of delivery of prophylactic medications should be investigated. 
3. Management of advanced RHD - National centres of excellence for the diagnosis, 
assessment and surgical management of RHD are required. Early referral for surgical 
input is necessary with multidisciplinary care and team-based decision making that 
includes patient, family, local health providers. There is a need for a national RHD 
surgical register and research strategy for the assessment, intervention and long-term 
outcome of surgery and other interventions for RHD. 
 
Keywords:  
Rheumatic fever 
Rheumatic heart disease  
Australia 
Indigenous population 
Prevention and control 
 
  
206 
 
Text 
Introduction 
Any discussion of the prevention, diagnosis and management of acute rheumatic fever 
(ARF) and rheumatic heart disease (RHD) will highlight the complexity inherent in 
providing an effective response to a condition that extends from acute through to chronic 
disease. Given the underlying association between ARF/RHD and socioeconomic 
disadvantage [1-3] such discussion must, by extension, involve multiple dimensions across 
all levels of health care and society more generally. 
 
In Australia, these diseases are almost exclusively borne by Aboriginal and Torres Strait 
Islander peoples, particularly those living in remote locations.[4-7] Geographical isolation 
and socioeconomic disadvantage, along with the need to provide long-term monitoring and 
care for those living with ARF/RHD, pose a number of major challenges to many patients, 
families, communities and health services. Delivery of ARF/RHD care in this setting is 
often less than optimal. Within this context, the aim of this workshop, undertaken as part of 
the CSANZ Indigenous Cardiovascular Health Conference in Alice Springs in 2011, was to 
identify priorities and provide guidance to inform the future response to the prevention, 
diagnosis and management of ARF and RHD in Australia and Oceania.  
 
Ten priority areas were identified through working with health service organisations and 
health care providers both before and during the workshop (see Box 1). Whilst time 
constraints meant only three were discussed in detail, they all provide a valuable insight 
into how stakeholders in health care can inform the future response to prevention and 
disease management. The discussions involved over fifty stakeholders in Australian and 
New Zealand health care who outlined the current understanding of these issues, identified 
gaps in knowledge and current practice, and provided recommendations and guidance to 
CSANZ and Australian jurisdictions regarding how these gaps may be addressed to 
improve outcomes for people living with ARF and RHD in our region. The overview of 
these discussions detailed below provides a valuable local and clinical perspective on 
ARF/RHD prevention and management that will be important in informing the future 
Australian response to these conditions. 
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1. Is there a role for echocardiography in the screening of high-risk populations and better 
diagnosis of RHD? 
2. Coordinating long-term care for people with RHD. 
3. Better and more appropriate management of advanced RHD.  
4. An appropriate and sustainable workforce. 
5. Getting secondary prophylaxis to work. 
6. Health determinants and the primordial prevention of ARF/RHD.  
7. Primary prevention and Group A Streptococcus 
8. Health promotion –communicating to patients, families, communities and health care.  
9. Getting ARF/RHD on the national health agenda - why did it take so long to be 
recognized as a priority and how can we ensure that it remains on the national health 
agenda? 
10. What are the systems issues that fail people living with ARF/RHD such that they do not 
receive the best practice care that they need? 
Box 1 - Priorities for addressing ARF/RHD in Australia 
 
Workshop Discussions and Recommendations 
The three priority areas addressed in detail were: 
1. Is there a role for echocardiography in screening and better diagnosis? 
2. Getting secondary prophylaxis to work. 
3. Better and more appropriate management of advanced RHD. 
For each of these issues a brief background was provided, gaps in current systems 
identified and potential solutions for addressing these gaps highlighted. 
 
1. Is there a role for echocardiography in screening and better diagnosis? 
Background 
Echocardiography is a crucial tool in diagnosing and assessing the severity of RHD.[8,9] 
With the availability of portable and relatively affordable echocardiography machines it is 
now possible to provide this to small and very remote communities as part of specialist 
outreach services. Nonetheless, there is ongoing debate regarding the details of valvular 
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morphologic change and the degree of functional impairment (regurgitation or stenosis) 
that are necessary to make a definitive diagnosis of RHD.[10] In particular, the question of 
whether potentially minor abnormalities of heart valve appearance or function represent the 
earliest signs of RHD remains unclear. Given this limitation the possible role of 
echocardiography in screening for early RHD cannot yet be fully addressed.  
 
Figure 1 – Screening echocardiography – portable and non-invasive but is it effective? 
 
Gaps 
In discussing the use of echocardiography in screening for, and the better diagnosis of, 
RHD a number of gaps in knowledge were identified including: 
• Based on existing uncertainty regarding interpretation, what should be done when 
echocardiography reveals minor changes in valve morphology? What are appropriate 
clinical algorithms for management of such minor abnormalities? 
• Valve (and particularly mitral valve) thickness as a morphologic feature of RHD – 
measures of valve thickness are dependent on machine settings (gain, focus, transducer 
frequency) which are difficult to standardise. It seems unlikely that it will be possible to 
identify early disease through an objective echocardiographic measure of leaflet 
thickness. 
• Are lower cost and more portable echocardiography machines comparable to 
those that are more expensive in the diagnosis and assessment of RHD? Anecdotal 
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evidence suggests lower cost portable machines may overstate the severity of valve 
lesions, especially for early disease. This is particularly important if the deployment of 
echocardiography-based screening programmes for RHD were considered with an 
attendant focus on early disease. 
• How could an echocardiography-based RHD screening programme be funded? 
Could it be resourced within existing service frameworks? 
• Can an echocardiography screening programme fulfil the criteria for “screening” if 
delivery of secondary prophylaxis remains poor? 
• What would be an appropriate service/workforce model of care if a screening 
programme were implemented. Options could include an expanded scope of practice 
for primary health care staff to undertake screening echocardiography, delivery by 
specialist-led teams or outreach echocardiographers, and/or telemedicine for review of 
acquired echocardiography studies and discussion of management. 
 
Solutions 
The response to some of the issues highlighted above is already underway. An extensive 
Australian screening study, the gECHO (getting Every Child’s Heart Okay) study, is 
nearing completion. This project (a collaboration between Baker IDI (Alice Springs), James 
Cook University (Cairns), Menzies School of Health Research (Darwin) and the University 
of Western Australia (Broome) supported by the Australian Department of Health and 
Ageing) undertook screening echocardiograms in 4000 Aboriginal and Torres Strait 
Islander children and 1000 non-Indigenous Australian children across northern Western 
Australia and Queensland, and the northern Top End and Centre of the Northern Territory. 
Preliminary results of gECHO identified a significant proportion of children with mild 
morphologic abnormalities, particularly of the mitral valve, of doubtful significance. In 
order to clarify the significance of these results, a follow up study is being undertaken.  
 
RhFFUS (Rheumatic Fever Follow-Up Study) is a prospective cohort study of children 
with non-specific mitral and/or aortic valve abnormalities that will examine whether such 
children are more likely to have an episode of ARF or develop RHD than children with 
normal heart valves. Supported by the National Health and Medical Research Council 
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(NHMRC), the findings of RhFFUS will provide clarity regarding the echocardiographic 
diagnosis of early RHD, help clinicians to better understand the significance of subtle 
changes on echocardiography, and inform the health service response for children with 
minor valve abnormalities. If such children are shown to have an increased risk of ARF 
and/or progression to RHD, then a case may be made for identifying high risk children 
earlier through screening echocardiography and offering them regular secondary 
prophylaxis to prevent progression to more severe RHD.  
 
Given the existing uncertainty it remains premature to advocate for, or incorporate, 
echocardiographic screening for RHD into Australian clinical practice. If results of 
gECHO and RhFFUS indicate that screening may be viable then the next step will be to 
undertake a detailed scoping and impact study focusing on how such a programme would 
be delivered and sustained, its cost and comparative cost-benefit, and how it would impact 
on the existing primary and specialist workforce. If a case cannot be made, or support 
obtained, for a national RHD screening programme, there may remain a rationale for 
screening on a quasi ad hoc basis within high risk communities and areas. 
2. Getting secondary prophylaxis to work 
Background 
Repeated episodes of ARF increase the likelihood that a person will develop RHD or will 
cause progression of RHD in those with minor disease.[11]If such repeated episodes of 
ARF can be prevented then the possibility of the development of severe RHD, with the 
attendant requirement for surgery to repair or replace damaged heart valves or other 
interventions, is reduced. For this reason, secondary prophylaxis in the form of four-weekly 
long-acting benzathine (LAB) penicillin injections is recommended for those who have had 
an episode of ARF or who have RHD.[9] The rationale for this treatment is the prevention 
of further GAS infections that may in turn lead to recurrent ARF. It should be noted that 
while there is good evidence that secondary prophylaxis for ARF/RHD is effective, oral 
antibiotics are inferior to intramuscular LAB in preventing recurrent ARF. The use of oral 
antibiotics is therefore only encouraged in patients with clear hypersensitivity to 
penicillin.[12] 
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While the effectiveness of secondary prevention is proven, achieving effective delivery and 
uptake of this has often been difficult.  There is no agreed benchmark for the uptake of 
secondary prophylaxis, and indeed anything less than 100% of doses is suboptimal. 
However, a generally utilised target for adequate uptake utilised in Australia is 80% of 
recommended LAB injections over a 12-month period. Unfortunately, data shows that 
relatively few Aboriginal and Torres Strait Islander individuals living with ARF/RHD 
achieve this level of secondary prophylaxis uptake.[13,14] While there is much anecdote 
regarding why the system is failing, there remains no clear evidence regarding how best to 
respond to this clear service gap. It is likely that one particular issue with secondary 
prophylaxis for ARF/RHD is the longevity and inconvenience of treatment. Clients 
accessing secondary prevention treatment usually have to undergo 10-20 years of painful 
four-weekly injections that may be perceived as having little benefit. The consequences of 
ARF/RHD are, like hypertension or kidney disease, only apparent once the disease is 
advanced at which time secondary prevention is often futile. 
 
Gaps 
Potential issues and service gaps influencing the uptake of effective secondary prevention 
for ARF/RHD were identified including: 
• While oral penicillin is not recommended, too many health professionals prescribe it 
in place of LAB injections. The protection provided by the variable use of oral 
antibiotics is not sufficient.[12] 
• Centralised RHD register and recall programmes are important in coordinating care. 
Nonetheless the Northern Territory experience would indicate that such systems alone 
cannot achieve the required levels of secondary prophylaxis uptake. 
• There are great disparities in the uptake of secondary prophylaxis in different 
communities. Successes should inform programme development. 
• In a primary health care environment faced with acute health care needs, secondary 
prophylaxis, like chronic disease management, is sometimes not seen as a priority.  
• Mobility of some Aboriginal and Torres Strait Islander patients can make it difficult for 
the health system to effectively deliver regular prophylaxis. 
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Solutions 
• Develop a sense of urgency and priority for the delivery of secondary prophylaxis in 
primary health care. Whilst primary care providers are faced with a broad range of 
health issues, all placing demands on finite time and resources, it is necessary to 
prioritise the delivery of secondary prophylaxis. Potential strategies include: 
− marketing (patient, family, community, health providers - “we're talking about 
children/the future”). 
− education (including utilising ‘clinical champions’/opinion leaders such as 
cardiologists and cardiac surgeons; introducing health provider training and 
professional development for all relevant primary health care providers and 
specialists). 
• Systems based approaches are required to ensure ARF/RHD fits within established 
chronic disease frameworks and systems. Active recall and follow-up is vital with 
effective health information management systems that allow the sharing of health data 
so that patients can access care at different health care centres and care items received 
are notified to a central database that can be widely accessed. There needs to be 
integration between central ARF/RHD registers and primary health care health 
information management systems. 
• Development and evaluation of primary health care-based or led strategies for delivery 
of secondary prophylaxis including: 
− Whose job is it? Is it important to have a dedicated person within the team who 
is responsible for ensuring prophylaxis is delivered? Does opportunistic delivery 
work when provided by all members of the primary health care team? The most 
effective and appropriate model for primary health care-based delivery of 
secondary prophylaxis should be a priority for future research. 
− Work flow - fast-tracking individuals presenting for their injection at clinics. 
− Basing timing of secondary prophylaxis on patient/community concepts of time 
– e.g. seasonal or community events (e.g. injections due on the full moon). 
− Communication and recall – what are patient, family, community needs and 
preferences? Is the concept of self-management appropriate in this setting? 
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− Continuous quality improvement initiatives to ensure better delivery of 
services. Focus on what the health service is doing rather than on what the 
patient is not doing.  
− Patient control and information ownership - Hand-held records for patients 
so that they can access secondary prophylaxis at any primary health care site. 
Participation in Australian national shared electronic health record (eHealth) 
initiative. 
− Incentives – Is there are role for reward system to encourage clients to achieve 
high levels of secondary prevention uptake? 
− Community-based delivery – alternate modes of delivery including the New 
Zealand model of secondary prophylaxis delivery by community-based public 
health nurses in schools and homes. 
− Smart recall systems – explore innovate methods for supporting clients and 
families and providing reminders through schools or workplace, or by using 
technology including SMS messaging, email and other internet based platforms. 
• Better methods of delivery - it is arguable that the delivery of secondary prophylaxis 
by 4-weekly LAB injections is a failed treatment model. A paradigm shift in the 
mechanism for delivery or a means of improving the delivery of intramuscular long-
acting penicillin is required. Investment in the development of innovative delivery 
systems for secondary antibiotic prophylaxis of ARF/RHD which are more convenient, 
less painful and longer-acting should be a priority. Given the small potential market, 
relying on commercial imperatives alone is unlikely to achieve this and strategic 
relationships with device and drug development organisations with a cost and risk-
sharing model will most likely be required. 
 
3. Better and more appropriate management of advanced RHD 
Background 
When the heart is no longer able to compensate for the abnormal 
functioning of damaged valves, heart failure results. This is most common 
in young adults, but is also sometimes seen in children.[4] Once valve 
damage is severe there are a broad range of options available dependent 
214 
 
both on patient circumstances and the degree and type of valve damage. Some options will 
not require the patient to be on lifelong anticoagulation (warfarin), a desirable outcome 
given the risks of bleeding and inconvenience of regular blood test monitoring. Other 
options will require warfarin therapy with its inherent inconvenience and complications 
including bleeding, valve thrombosis and embolisation. Furthermore, some surgical 
interventions rarely require repeat intervention (mechanical valves) while others may 
eventually require later operations (bioprosthetic valves, valve repair, balloon 
valvuloplasty). The choice and timing of intervention therefore needs to carefully balanced 
taking into account patient preferences, the safety of anticoagulation and the risk of later 
reoperation before proceeding with any particular course of action. 
 
In Australia, patients with RHD who require surgery are routinely transferred to one of 
approximately thirty city-based cardiothoracic surgical units. Given the number of units 
involved it is hardly surprising that the surgical management of RHD varies widely. For 
example, patients with mitral regurgitation, the most common valve damage seen in RHD, 
may undergo valve repair or a valve replacement with a mechanical or bioprosthetic valve; 
which occurs is often more dependent on where the operation is undertaken rather than on 
the application of consistent and objective criteria. This is perhaps why, once the patient 
returns to their usual health care providers, questions may arise regarding whether the 
intervention undertaken was the most appropriate option.  
 
A similar situation exists for mitral stenosis. While percutaneous balloon valvuloplasty is 
an effective and comparatively safe treatment for mitral stenosis, particularly in younger 
and pregnant patients, there are few centres in Australia that undertake this in large 
numbers. If patients with mitral stenosis are referred to cardiothoracic surgeons anecdotal 
reports would indicate there can be a tendency to operate and replace the valve rather than 
to undertake balloon valvuloplasty. 
 
The problem of inconsistency in surgical and other interventions (e.g. percutaneous balloon 
valvuloplasty) for the management of advanced RHD is further exacerbated by the fact that 
most patients undergo surgery in major city centres far removed from the realities of the 
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remote communities or regional centres where they usually live. This often entails a 
disconnection between the decisions being made by tertiary hospital-based specialists and 
surgeons, local primary and specialist health care providers, and the practical aspects of life 
and health service access in regional and remote Australia. 
 
Gaps 
• Mitral valve repair – The use of mitral valve repair versus mitral valve replacement 
for RHD varies greatly between different cardiothoracic surgical centres in Australia. 
Overall in Australia there is a general lack of experience with surgical repair as opposed 
to valve replacement.  
• Delay in presentation - patients with RHD can first present for primary and specialist 
health care with symptomatic and advanced disease that requires early and occasionally 
urgent surgical intervention.  This has particular implications for the suitability for 
mitral valve repair as late referral often means valve damage is extensive and mitral 
valve repair is not possible. 
• Consistency and leadership in the surgical management of RHD – the diversity of 
the management of advanced RHD across Australia has been noted. There are no 
national centres of excellence for specialist RHD diagnosis, severity assessment and 
management.   
• Multidisciplinary team management of advanced RHD – decisions regarding the 
details of management of advanced RHD are frequently undertaken by cardiothoracic 
surgical teams. This can often occur without broader input from the patient/family and 
other health care providers (including local primary health care providers and regional 
and visiting specialists) particularly with regard to the implications for local follow-up, 
the need for anticoagulation, future pregnancy, re-operation and infective endocarditis 
risk.  
 
Solutions 
• Improved understanding of health care access and uptake of secondary 
prophylaxis - issues pertaining to secondary prophylaxis for ARF/RHD are discussed 
above. A greater understanding is also required in relation to why patients are lost to 
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follow-up, how to identify RHD in women before they may become pregnant and how 
to encourage the early presentation and appropriate investigation of patients with 
unexplained shortness of breath. 
• National centres of excellence for the diagnosis, assessment and surgical management 
of RHD are required. Health staff, particularly those at primary health care sites where 
most health care for people with ARF/RHD occurs, should be able to easily contact 
clinical experts who can provide consistent evidence-based advice that reflects the 
realities of regional and remote Australian life and clinical practice.  
• Multidisciplinary care and team-based decision making for the planning of 
intervention for RHD. Decision-making needs to involve those who will be faced with 
the aftermath of intervention/surgery (i.e. patients, families and local primary and 
specialist health care providers).  
• Early referral for surgical input would allow a broader range of options for 
intervention to be considered. Multidisciplinary and team-based decision making would 
encourage this particularly if such input could be provided locally either by 
telemedicine or through cardiothoracic surgical outreach to regional centres. 
• National RHD surgical register and research strategy for the assessment, 
intervention and long-term outcome of surgery and other interventions for RHD. A 
priority is the development of a surgical management and outcome register that 
incorporates details regarding a standardised baseline assessment, documents the 
rationale for the intervention chosen, and allows short and long-term follow-up which 
includes re-operation, readmission, morbidity (including stroke and endocarditis) and 
survival. Where possible, additional measures incorporating objective assessments of 
function (six minute walk test) and quality of life should be included. This will enable 
the development of evidence-based recommendations for surgical and other 
interventions in the management of advanced RHD in Australia and have significant 
implications for international practice. 
• Improving the use of warfarin – warfarin is likely to remain a reality of RHD 
management. Research to enhance the understanding of how patients and primary 
health care providers perceive long-term anticoagulation and how monitoring and 
regular use of warfarin can be enhanced should be a priority. 
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Additional issues pertaining to ARF/RHD care discussed in less detail 
Whilst there were at least seven other areas that were not discussed in any detail the 
primordial and primary prevention of ARF/RHD was a recurring theme. 
 
Primary prevention and Group A Streptococcus – where to from here? 
Whilst not all patients presenting with ARF have a history of pharyngitis[15], the early 
treatment of Group A Streptococcus (GAS) associated pharyngitis provides an effective 
opportunity to prevent the development of ARF.[16,17] New Zealand experience would 
indicate that there is limited awareness of the importance of the early management of 
pharyngitis in high-risk (Māori and Pacific Islander) populations both in community 
members and health care providers. Research investigating the understanding of how 
communities at high risk of ARF/RHD and local primary health services perceive and 
respond to pharyngitis (including seeking health care review) is required. This should 
inform community and health provider education initiatives to ensure pharyngitis prompts 
primary health care review and that primary health care providers have clear and consistent 
protocols for confirming a diagnosis of GAS-associated pharyngitis or treatment protocols 
for empiric management. 
 
Conclusion 
The Cardiac Society of Australia and New Zealand’s Alice Springs 2011 Indigenous 
Cardiovascular Health Conference provided a unique and valuable opportunity for experts 
with ‘on the ground experience’ in primary and specialist health care delivery and planning 
to gather and identify shared priorities in the Australian response to ARF/RHD (see Box 2). 
Although time was limited this group provided clear recommendations to inform the local, 
jurisdictional and national response to ARF/RHD. There remains much to be done and 
many unanswered questions. Nonetheless, it is hoped this document helps chart a course for 
addressing what is a complicated health issue in regional and remote Australia and for 
Aboriginal and Torres Strait Islander peoples. 
 
As one participant noted: 
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‘I work in the primary health area. I've been in Aboriginal health for a long time. To think 
that rheumatic fever has been around for a very long time, and is only just got on the 
agenda, and it's making me think, yeah, I've... got relatives and family who's got rheumatic 
fever. We talk about diabetes, we talk about HIV / AIDS... but to me this has just come on 
the agenda.’ 
 
It is imperative that ARF/RHD now remains on the national and international health 
agenda. With the support and advocacy of CSANZ and the ongoing advice and 
commitment from patients, communities and health providers, ARF/RHD can be largely 
eradicated as it has been for non-Indigenous Australians.  
 
1. Echocardiography and Screening/Diagnosis of RHD - Given the existing uncertainty 
it remains premature to advocate for or to incorporate echocardiographic screening for 
RHD into Australian clinical practice. Further research is currently being undertaken to 
evaluate the potential for echocardiography screening. 
2. Secondary Prophylaxis – Secondary prophylaxis (LAB injections) must be seen as a 
priority. Systems-based approaches are necessary with a focus on the development and 
evaluation of primary health care-based or led strategies incorporating effective health 
information management systems. Better/novel systems of delivery of prophylactic 
medications should be investigated. 
3. Management of Advanced RHD - National centres of excellence for the diagnosis, 
assessment and surgical management of RHD are required. Early referral for surgical 
input is necessary with multidisciplinary care and team-based decision making that 
includes patient, family, local health providers. There is a need for a national RHD 
surgical register and research strategy for the assessment, intervention and long-term 
outcome of surgery and other interventions for RHD. 
Box 2. Summary of recommendations from the CSANZ Indigenous Cardiovascular Health 
Conference 2011 – ARF/RHD workshop. 
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